Cost-Effectiveness Analysis for Therapy Sequence in Advanced Cancer: A Microsimulation Approach with Application to Metastatic Prostate Cancer

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

(2022) Karim Fizazi et al.   LANCET

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

(2021) Peng-Fei Zhang et al.   BMC CANCER

Comparison of Decision Modeling Approaches for Health Technology and Policy Evaluation

(2021) John Graves et al.   MEDICAL DECISION MAKING

Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness

(2020) Vera Hirsh et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma

(2019) Edward J Gibson et al.   JOURNAL OF MEDICAL ECONOMICS

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

(2019) Ian D. Davis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer

(2019) Chethan Ramamurthy et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

(2019) Vakaramoko Diaby et al.   BREAST

Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy

(2018) Loay Kassem et al.   CURRENT MEDICAL RESEARCH AND OPINION

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer

(2018) Alicia K. Morgans et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

(2018) Kim N Chi et al.   LANCET ONCOLOGY

Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial

(2018) Eline M. Krijkamp et al.   MEDICAL DECISION MAKING

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

(2017) Mario Eisenberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma

(2017) Christine G. Kohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Generalizability analysis for clinical trials: a simulation study

(2017) Wei Wang et al.   STATISTICS IN MEDICINE

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer

(2017) Neal Shore et al.   UROLOGY

Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

(2016) Vakaramoko Diaby et al.   BREAST CANCER RESEARCH AND TREATMENT

Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer

(2016) Maria Carmen Riesco-Martínez et al.   Journal of Oncology Practice

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

(2015) Daniel P Petrylak et al.   LANCET ONCOLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

(2013) Lixian Zhong et al.   PLoS One

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

State-Transition Modeling

(2012) Uwe Siebert et al.   MEDICAL DECISION MAKING

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

(2012) Charles J. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cost–utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer

(2011) T. Younis et al.   Current Oncology

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states

(2009) Gary H. Lyman et al.   CLINICAL THERAPEUTICS